ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

BACKGROUND: ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cisplatin r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Clin Cancer Res
Päätekijät: Zhu, Linlin, Zou, Jiao, Zhao, Yuanyin, Jiang, Xiaomei, Wang, Yang, Wang, Xiangwei, Chen, Bin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019204/
https://ncbi.nlm.nih.gov/pubmed/29940998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0798-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia